Skip to content
drillr.ai
Sign up

CBLL

Ceribell, Inc.

NASDAQ · Healthcare · Medical - Devices · US

$27.47
−2.84%
Ask drillr

  • Nov 4, 2026, 01:56 UTC

    Ceribell, Inc. reported a third-quarter loss of $0.48 per share, compared with a loss of $0.37 per share a year earlier.

    Source:

  • Nov 3, 2026, 21:05 UTC

    Ceribell reported financial results for the third quarter ended September 30, 2026.

    Source:

  • Nov 2, 2026, 12:00 UTC

    Ceribell announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.

    Source:

  • Oct 20, 2026, 20:05 UTC

    Ceribell, Inc. announced that it will release its third-quarter 2026 financial results after market close on November 3, 2026, and hold a conference call that day at 1:30 p.m. PT (4:30 p.m. ET).

    Source:

  • Sep 18, 2026, 01:45 UTC

    Ceribell CFO Scott Blumberg exercised options for 846 shares at $9.41 and sold the same 846 shares for $21,150 on September 15, 2026, under a Rule 10b5-1 plan adopted December 12, 2025.

    Source:

  • Aug 25, 2026, 23:50 UTC

    Ceribell President and CEO Chao Xingjuan sold 6,068 shares of Ceribell common stock at $24.02 per share, totaling $145,753, on August 21, 2026, to cover tax withholding obligations related to RSU vesting.

    Source:

  • Aug 11, 2026, 09:28 UTC

    CeriBell, Inc. held its Q2 2026 earnings call on August 11, 2026, to discuss financial results.

    Source:

  • Aug 10, 2026, 22:56 UTC

    CeriBell, Inc. reported a second-quarter loss of $0.51 per share, missing the Zacks Consensus Estimate of a $0.45 loss and widening from a $0.38 loss a year earlier.

    Source:

  • Aug 10, 2026, 22:04 UTC

    CeriBell plans to commercially launch its delirium-monitoring solution later this year.

    Source:

  • Aug 10, 2026, 11:00 UTC

    Ceribell received FDA 510(k) clearance for two new AI algorithm enhancements, Epileptiform Abnormality Detection and Artifact Reduction, integrated into its cloud-based Neurology Portal for critical-care EEG review.

    Source:

  • Aug 3, 2026, 11:00 UTC

    Ceribell received CMS New Technology Add-On Payment (NTAP) for its point-of-care delirium monitor system, which may broaden access to its dual seizure and delirium monitoring platform.

    Source:

  • Jul 30, 2026, 00:00 UTC

    Ceribell, Inc. appointed William W. Burke as a Class II director, Joseph M. Taylor as a Class III director, Sharon L. O'Keefe as a Class I director, and Thomas A. West as a Class I director, effective July 28, 2026.